{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreig6syqjjbi4ysmeehpk3rve4cyt3df6r3shuso6jxsorej2qrpgxu",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3me6dlghbdgz2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreif6cyqxlfnlfosypoxayhzxg2zs44zibz7fukkknq7p6btktofc3m"
    },
    "mimeType": "image/jpeg",
    "size": 83511
  },
  "path": "/2026/02/05/corcept-therapeutics-fda-relacorilant-cushings-disease/?utm_campaign=rss",
  "publishedAt": "2026-02-05T11:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Adam's Biotech Scorecard",
    "Adam's Take",
    "Biotech",
    "biotechnology",
    "Cancer",
    "chronic disease",
    "Pharmaceuticals",
    "rare diseases",
    "STAT+"
  ],
  "textContent": "A liver-safety risk puts the future of Corcept Therapeutics' experimental drug in doubt.",
  "title": "STAT+: Dispute between Corcept Therapeutics, FDA runs deep",
  "updatedAt": "2026-02-05T11:49:51.000Z"
}